Pharmacy · Independent exam preparation
薬剤師国家試験: Mechanisms, Calculations and Safe Pharmacy Decisions Study Guide
Practise drug mechanisms, pharmaceutical calculations, treatment selection, Japanese professional duties and patient safety decisions across all seven pharmacist examination subjects.
By CertMedbry · Updated 30 October 2026
Connect drug mechanisms to laboratory findings, compare therapeutic choices, calculate pharmaceutical quantities, resolve prescription problems and explain medicines clearly to patients. This selective 60-concept guide develops those decisions across the seven official subjects, with particular attention to practical pharmacy. The official 薬剤師国家試験出題基準 remains the reference for the full scope; candidates should also study its topics beyond this selection.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and qualification does this guide address?
薬剤師国家試験 is Japan's national pharmacist licensing examination administered by 厚生労働省. The main eligibility pathway is completion of the qualifying six-year university pharmacy curriculum. The examination is part of pharmacist licensure; passing alone does not replace the licensing and registration requirements.
Do foreign-qualified or historical eligibility routes represent different examinations?
The current notice also describes ministerially recognized foreign qualifications and specified transitional eligibility routes. These are eligibility routes to the same 薬剤師国家試験, rather than separate specialty examinations. This guide follows the current seven-subject examination, not an earlier four-year curriculum or a separate foreign pharmacist credential.
How many questions are published, and is there a scored/pretest split?
The published structure specifies 345 questions: 90 essential questions, 105 pharmaceutical theory questions and 150 pharmaceutical practice questions. The cited structure does not identify a separate unscored pretest allocation. A scored/pretest breakdown therefore should not be inferred from the total.
What question styles and linked items does the examination use?
Essential questions generally use five-option single-answer questions. General questions may require multiple correct selections or other selection formats. The practice section contains 20 standalone practical questions and 130 questions linking practical pharmacy with other subjects. The 20 four-option questions accompanying this guide are independent learning drills, not a reproduction of the full examination format.
薬剤師国家試験出題基準 — 平成28年11月22日 · 新薬剤師国家試験について — amended through 2018-08-31
What duration, delivery arrangement and examination dates are verified?
The published structure provides six sessions over two days: 90, 150 and 115 minutes on day one; 125, 100 and 150 minutes on day two. These total 730 examination minutes, excluding breaks. The 112th examination notice specifies 20–21 February 2027 at designated Japanese examination locations. The materials establish scheduled subject sessions; they do not verify a computer-adaptive format or specify paper versus computer delivery.
新薬剤師国家試験について — amended through 2018-08-31 · 薬剤師国家試験 — 第112回薬剤師国家試験の施行
Which blueprint applies, and when does the planned replacement begin?
The applicable seven-subject outline was finalized on 22 November 2016 and applies from the 106th examination, held in February 2021. The 112th notice retains those subjects. The 2026 revision proceedings concern a replacement planned for fiscal 2029 and the 115th examination; that future subject structure is not the basis of this guide.
薬剤師国家試験出題基準 — 平成28年11月22日 · 新たな薬剤師国家試験出題基準を策定しました · 薬剤師国家試験出題基準改定に係る経緯について · 薬剤師国家試験出題基準改定部会 — 2026-06-01 meeting minutes
How is subject coverage weighted?
Official subject totals are 60 for 物理・化学・生物; 40 each for 衛生, 薬理, 薬剤 and 病態・薬物治療; 30 for 法規・制度・倫理; and 95 for 実務. Calculated shares are approximately 17.39%, 11.59% each, 8.70% and 27.54%, respectively. This guide allocates its concepts 10/7/7/7/7/5/17 and its questions and cards 4/2/2/2/2/2/6. These are rounded educational allocations.
Is there a fixed overall passing percentage?
The published framework uses a relative overall standard based on difficulty-adjusted scores, the mean and standard deviation. It also requires at least 70% of essential-question points overall and at least 30% in each essential subject, with consideration of contraindicated selections. These conditions do not establish one permanent overall raw-score cutoff. Performance on this short learning test does not predict passing.
This English-language guide addresses Japan's national pharmacist licensing examination administered by 厚生労働省, using the current seven-subject pathway associated with six-year pharmacy education. It is independently authored educational material. International references support scientific principles and safety reasoning; Japanese professional duties use Japanese authorities.
Outline used: Verified as of 2026-10-11 Asia/Hong_Kong. The workbook label 'Japan National Pharmacist Examination' maps to the official 薬剤師国家試験; the assigned slug is preserved. Applicable outline: 薬剤師国家試験出題基準, finalized 2016-11-22 and effective from the 106th examination in fiscal 2020, held in February 2021. The current 112th examination notice, dated 2026-08-28, retains the seven-subject structure. The 2026 revision proceedings schedule a replacement outline for examinations from fiscal 2029; that future outline is not used here.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
物理・化学・生物60/345 items; 17.39% calculated
1.How does the conjugate-base ratio determine buffer pH?
A weak acid and its conjugate base resist pH changes by consuming added base and acid, respectively. For an appropriate buffer, the Henderson–Hasselbalch relationship is pH = pKa + log10([A−]/[HA]). Equal concentrations give pH equal to pKa; a tenfold excess of conjugate base raises pH by one unit. Identify the conjugate pair before calculating, and use the amounts remaining after any neutralization rather than the original mixing ratio.
Apply it
An analytical buffer has pKa 6.2 and contains 0.020 mol conjugate base with 0.010 mol weak acid in the same volume. Its estimated pH is 6.2 + log10(2), approximately 6.50.
Common pitfall: Reversing the base-to-acid ratio reverses the predicted pH shift. Applying the equation before accounting for added strong acid also gives the wrong composition.
Chemistry 2e — 14.6 Buffers · 14.6 Buffers - Chemistry: Atoms First | OpenStax
2.Why can two buffers share a pH but differ in capacity?
Buffer pH primarily reflects the ratio of conjugate base to weak acid, whereas capacity also depends on their total concentration. A concentrated buffer can consume more added acid or base before its ratio changes substantially. Capacity is greatest near pKa, where both components are appreciably present. Diluting both components equally approximately preserves their ratio and initial pH, but reduces the amount of added acid or base that the solution can accommodate.
Apply it
Two equal-volume buffers each have equal acid and conjugate-base concentrations. One contains 0.10 mol/L of each component and the other 0.010 mol/L. Both initially have pH near pKa, but the concentrated buffer better resists an identical acid addition.
Common pitfall: A correct starting pH does not guarantee useful buffering during an assay. A highly diluted solution may have the desired ratio but little reserve.
Chemistry 2e — 14.6 Buffers · 14.6 Buffers - Chemistry: Atoms First | OpenStax
3.How do absorbance and transmittance distinguish concentration changes?
Transmittance is transmitted light divided by incident light, and absorbance is its negative base-ten logarithm. Under Beer–Lambert conditions, absorbance equals absorptivity multiplied by optical path length and concentration. Doubling concentration doubles absorbance, not the percentage of light absorbed. Use a suitable blank and the same wavelength and path length when comparing samples. The historical ministry analytical-method reference supports these stable relationships rather than establishing a current pharmacopoeial procedure.
Apply it
A solution has absorbance 0.30 in a one-centimetre cell. After an exact twofold dilution, the expected absorbance is 0.15 if the analyte remains unchanged and the measurement stays within the method's linear range.
Common pitfall: Treating transmittance as directly proportional to concentration ignores its logarithmic relationship with absorbance. Turbidity or chemical changes can also invalidate simple concentration comparisons.
4.What makes two molecules enantiomers?
Enantiomers are non-superimposable mirror-image stereoisomers with the same atom connectivity. A tetrahedral carbon attached to four different substituents is a common source of chirality. Biological receptors and enzymes are themselves chiral, so mirror-image drugs can interact differently with them. Distinguish a change in spatial arrangement from a change in connectivity, and distinguish a molecule's configuration from the experimentally measured direction in which it rotates plane-polarized light.
Apply it
Two candidate structures have identical bonds and one tetrahedral carbon bearing four different substituents. Their mirror images cannot be superimposed by rotation. Classify them as enantiomers before considering whether a chiral biological target distinguishes their effects.
Common pitfall: An R designation does not establish positive optical rotation. Molecules with different connectivity are constitutional isomers, even when their molecular formulas are identical.
Organic Chemistry — 5.1 Enantiomers and the Tetrahedral Carbon · 5.5 Sequence Rules for Specifying Configuration - Organic Chemistry | OpenStax
5.How are priorities used to assign R or S configuration?
Rank the four substituents at a tetrahedral stereocentre using the Cahn–Ingold–Prelog rules. Higher atomic number takes priority; heavier isotopes take priority when the element is the same. If directly attached atoms tie, compare successive attached atoms until the first difference. Multiple bonds are treated using duplicate-atom comparisons. Orient the lowest-priority substituent away: a clockwise path through priorities one, two and three gives R; counterclockwise gives S.
Apply it
For 2-chlorobutane, the priorities are chlorine, ethyl, methyl and hydrogen. With hydrogen directed away, a clockwise chlorine-to-ethyl-to-methyl sequence assigns R configuration.
Common pitfall: Reading the sequence with the lowest-priority group toward the viewer reverses the assignment. R/S configuration does not determine the sign of optical rotation.
薬剤師国家試験出題基準 — 平成28年11月22日 · 5.5 Sequence Rules for Specifying Configuration - Organic Chemistry | OpenStax
6.How does a prodrug differ from an active metabolite?
A prodrug is an administered precursor that undergoes biotransformation to an active drug responsible for its therapeutic activity. Intentional structural modification to improve absorption, distribution or another pharmaceutical property is a common development strategy, but deliberate design is not a defining requirement; prodrug activity can also be discovered unexpectedly. An active metabolite is a pharmacologically active product of metabolism and can arise from an already active parent. The key distinction is activation-dependent activity. Reduced activation can lower prodrug effect even when parent-drug concentrations rise.
Apply it
An experimental ester has little intrinsic activity but is hydrolysed to an active carboxylic acid after absorption. Interpret the ester as a prodrug and consider conversion efficiency when comparing exposure to the active species across subjects.
Common pitfall: Metabolism does not always inactivate a medicine. Finding an active metabolite from an already active parent does not by itself establish that the parent is a prodrug, and an unexpected discovery does not exclude prodrug classification.
薬剤師国家試験出題基準 — 平成28年11月22日 · Serendipitous discovery of a prodrug of a PARP-1 inhibitor - PubMed
7.How does competitive enzyme inhibition change substrate requirements?
In the simple reversible competitive model, the inhibitor binds free enzyme and its binding is mutually exclusive with substrate binding. This often involves the substrate's binding site, but identical binding locations are not required. Apparent Km increases while Vmax remains unchanged; sufficiently high substrate can overcome inhibition in this model. Pure noncompetitive inhibition instead lowers Vmax without changing Km, while uncompetitive inhibition lowers both. These patterns require measurements across substrate concentrations under appropriate steady-state conditions.
Apply it
An enzyme assay reaches the same maximal velocity with and without an inhibitor, but requires a higher substrate concentration in its presence. Under the stated simple kinetic assumptions, this pattern supports reversible competitive inhibition.
Common pitfall: A lower reaction rate at one substrate concentration cannot identify the inhibition mechanism. Allosteric binding also does not automatically imply a noncompetitive kinetic pattern.
薬剤師国家試験出題基準 — 平成28年11月22日 · Mechanism of Action Assays for Enzymes - Assay Guidance Manual - NCBI Bookshelf
8.How does oxidative phosphorylation connect oxygen to ATP production?
Electron transport in the inner mitochondrial membrane transfers electrons from reduced carriers toward oxygen, which is reduced to water. Energy released during transport drives proton movement from the matrix into the intermembrane space. Protons returning through ATP synthase down their electrochemical gradient drive ATP formation from ADP and inorganic phosphate. An uncoupler increases proton leakage, weakening this gradient and reducing ATP production while dissipating energy as heat.
Apply it
In a hypothetical mitochondrial experiment, the inner membrane becomes freely permeable to protons. The proton gradient dissipates, so ATP synthesis falls despite continued availability of respiratory substrates and oxygen. The defect concerns coupling, rather than a shortage of ADP alone.
Common pitfall: Oxygen availability does not guarantee effective oxidative phosphorylation. An intact gradient and functional ATP synthase are also required to convert respiratory energy into ATP.
薬剤師国家試験出題基準 — 平成28年11月22日 · 7.4 Oxidative Phosphorylation - Biology for AP® Courses | OpenStax
9.Why does active immunity produce memory while passive immunity does not?
Active immunity follows the person's own immune response to an antigen, as after infection or vaccination, and can generate memory cells. Passive immunity supplies preformed antibodies, providing protection without requiring that initial immune response. Its protection wanes as the transferred antibodies are lost and does not itself create antigen-specific memory. The discriminating cue is whether the recipient generates the response or receives its antibody product, not whether the intervention is given by injection.
Apply it
A person receives an antibody preparation for immediate protection after an exposure. Explain that this is passive immunity: antibodies are supplied directly, while durable immune memory would require an appropriate active immune response to antigen.
Common pitfall: Injection is not synonymous with vaccination or active immunity. Injected antibodies and injected vaccines differ in what is delivered and how protection develops.
10.Which biological feature separates viruses from independently growing bacteria?
Bacteria are cellular organisms with their own ribosomes and metabolic machinery, although their growth requirements vary. Viruses depend on host cells for replication and do not possess a complete independent cellular system. This distinction explains why a bacterial target cannot simply be assumed to exist in a virus. Identify the organism and relevant target before reasoning about an antimicrobial mechanism; the broad category of infection alone does not establish susceptibility.
Apply it
A laboratory comparison describes one agent multiplying by cellular division and another producing new particles only inside susceptible host cells. The second description supports a virus and argues against assuming that bacterial cell-wall synthesis is its replication target.
Common pitfall: Small size alone does not reliably distinguish all infectious agents. Likewise, an antibiotic's activity against bacteria does not imply useful activity against a viral infection.
衛生40/345 items; 11.59% calculated
11.How is a risk ratio calculated in a cohort?
A cohort study can compare the occurrence of an outcome in exposed and unexposed groups whose denominators are known. Divide risk in the exposed group by risk in the comparison group to obtain the risk ratio. A value above one indicates a higher observed risk; a value below one indicates a lower observed risk. Interpretation still depends on follow-up, outcome definition, uncertainty and confounding, so an association alone does not establish causation.
Apply it
During identical follow-up, 30 of 300 exposed people and 10 of 200 unexposed people develop an outcome. Risks are 0.10 and 0.05, giving a risk ratio of 2.0. The exposed group's observed risk is twice as high.
Common pitfall: Comparing case counts without denominators can reverse an interpretation. A risk ratio also needs a stated comparison direction and comparable observation periods.
CDC Field Epidemiology Manual — Analyzing and Interpreting Data
12.Why is an odds ratio useful in a case-control study?
Case-control studies select participants according to outcome status and then compare prior exposures. Because investigators determine the sampled numbers of cases and controls, disease risk usually cannot be calculated directly from those group totals. The exposure odds ratio compares exposure odds among cases with exposure odds among controls. It can approximate a risk ratio under appropriate conditions, particularly a rare outcome, but it is not generally interchangeable with risk.
Apply it
Among 80 cases, 40 were exposed; among 120 controls, 30 were exposed. Exposure odds are 40/40 and 30/90. Their ratio is 3.0, indicating an exposure association rather than directly showing a threefold disease probability.
Common pitfall: Using the proportion of sampled cases as population incidence ignores outcome-based sampling. An odds ratio can also substantially exceed a risk ratio for common outcomes.
CDC Field Epidemiology Manual — Analyzing and Interpreting Data
13.How can confounding create a misleading exposure association?
A confounder is associated with the exposure and independently related to the outcome, without being an intermediate step in the proposed causal pathway. Unequal distributions can produce or distort an apparent exposure effect. Stratification and appropriate adjustment help examine this problem; neither automatically removes all bias. A useful clue is a marked change between crude and appropriately adjusted estimates, especially when the third variable has a plausible relationship with both exposure and disease.
Apply it
An observational study finds more cardiovascular events among users of a medicine, but users are substantially older. Compare age-specific or adjusted results before attributing the difference to treatment, because age may explain part of the crude association.
Common pitfall: Adjusting for every measured variable is not automatically sound. Controlling an intermediate variable can obscure the effect the study was intended to estimate.
CDC Field Epidemiology Manual — Analyzing and Interpreting Data
14.Which prevention level matches vaccination, screening and rehabilitation?
Primary prevention aims to prevent disease from developing, secondary prevention seeks early detection and intervention, and tertiary prevention limits consequences of established disease. Vaccination illustrates primary prevention; screening asymptomatic people for early disease illustrates secondary prevention; rehabilitation after disease-related disability illustrates tertiary prevention. Classify the purpose and disease stage rather than the location or profession delivering the intervention. The same clinical service can contain activities serving different prevention levels.
Apply it
A community programme offers vaccination, early disease screening and rehabilitation support after stroke. Map these activities to primary, secondary and tertiary prevention, respectively, using whether disease onset, early detection or established disability is being addressed.
Common pitfall: Screening does not prevent the initial biological onset of the disease it detects. Calling every preventive service primary prevention loses the disease-stage distinction.
薬剤師国家試験出題基準 — 平成28年11月22日 · CDC Pink Book — Chapter 1: Principles of Vaccination
15.How do energy-yielding nutrients differ from micronutrients?
Carbohydrate, fat and protein can provide metabolic energy, while vitamins and minerals support physiological functions without serving as equivalent energy substrates. Nutritional adequacy therefore requires more than a sufficient calorie total. A diet may meet energy needs but lack essential nutrients, or contain appropriate micronutrients while providing insufficient energy. Assess composition alongside quantity, and distinguish biochemical roles from claims that a supplement itself supplies usable dietary energy.
Apply it
A dietary record shows adequate total energy but very limited food variety over several months. The appropriate nutritional concern is possible nutrient imbalance despite adequate calories; an energy total alone cannot establish sufficient vitamin, mineral or protein intake.
Common pitfall: More calories do not correct every nutritional deficiency. Similarly, vitamin supplementation does not replace the energy and protein needed when total food intake is inadequate.
16.Why does refrigeration differ from sterilization in food safety?
Refrigeration slows growth of many microorganisms and slows some chemical changes, but it does not reliably eliminate all organisms or preformed toxins. Sterilization has the different objective of eliminating viable microorganisms through an appropriate validated process. Food safety therefore depends on preventing contamination and controlling storage and processing conditions together. A cold product can remain contaminated, and later warming can permit surviving organisms to multiply if other conditions allow growth.
Apply it
A food container is refrigerated after suspected contamination. A learner proposes that cooling has made it sterile. Reject that conclusion: reduced growth rate does not demonstrate organism elimination, and the contamination history remains relevant to safety assessment.
Common pitfall: Absence of visible spoilage does not establish microbiological safety. Refrigeration is a preservation measure, not proof that pathogens or their toxins are absent.
17.Why can conventional pulse oximetry miss carbon monoxide poisoning?
Carbon monoxide forms carboxyhemoglobin and impairs oxygen delivery. Conventional two-wavelength pulse oximetry cannot reliably distinguish carboxyhemoglobin from oxyhemoglobin, so an apparently reassuring saturation does not exclude poisoning. Exposure circumstances, symptoms and carboxyhemoglobin measurement by appropriate co-oximetry are more discriminating. Interpret the measured level alongside time since exposure and oxygen treatment, because the level can fall before testing and does not consistently track clinical severity.
Apply it
Several occupants develop headache and nausea after using a fuel-burning heater indoors. One has a conventional pulse-oximeter reading of 99%. The shared exposure remains concerning, and appropriate carboxyhemoglobin testing is warranted despite that reading.
Common pitfall: A normal conventional saturation is not a rule-out test for carbon monoxide exposure. A delayed low carboxyhemoglobin result also requires interpretation within the exposure timeline.
薬理40/345 items; 11.59% calculated
18.How does beta-2 receptor activation relax bronchial smooth muscle?
Albuterol stimulates beta-2 adrenergic receptors, activating adenylate cyclase and increasing intracellular cyclic AMP. This signalling promotes bronchial smooth-muscle relaxation and bronchodilation. The receptor and second messenger identify the mechanism more precisely than the general statement that the drug improves breathing. Distinguish reversal of bronchoconstriction from treatment of every cause of breathlessness, and recognize that symptomatic improvement does not by itself establish control of the underlying airway disease.
Apply it
A pharmacology exercise asks why airway calibre increases after a beta-2 agonist. Trace the response from receptor activation to increased cyclic AMP and smooth-muscle relaxation, rather than assigning the effect to direct histamine neutralization.
Common pitfall: Bronchodilation does not prove that inflammation has resolved. Confusing beta-2 agonism with muscarinic blockade produces the right general outcome through the wrong molecular explanation.
19.How do potency and maximal efficacy differ?
Potency concerns the concentration or dose needed to produce a specified effect, whereas maximal efficacy concerns the greatest effect achievable under defined conditions. A left-shifted concentration–response curve indicates greater potency when comparable effects are measured, but does not necessarily indicate a higher maximum. Compare both the horizontal position and the plateau. These experimental properties do not independently establish superior clinical benefit, which also depends on exposure, safety and the relevant outcome.
Apply it
Two experimental agonists reach the same maximal response, but one reaches half-maximal response at a lower concentration. Describe that agonist as more potent in this system, without claiming that its maximal efficacy is greater.
Common pitfall: A smaller numerical dose does not automatically make a medicine clinically better. Potency comparisons also become misleading when routes, endpoints or experimental systems differ.
20.How does ACE inhibition reduce angiotensin-mediated effects?
Lisinopril inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II. Lower angiotensin II reduces vasoconstrictor activity and aldosterone secretion. This links blood-pressure effects with a potential reduction in renal potassium excretion. The discriminating target is the converting enzyme, rather than the angiotensin receptor or renin itself. Follow the pathway to explain both intended haemodynamic effects and predictable electrolyte risks without assuming every patient experiences the same response.
Apply it
A learner must connect a blood-pressure medicine with a rising potassium concentration. Identifying lisinopril as an ACE inhibitor provides a mechanistic link: reduced angiotensin II lowers aldosterone-mediated potassium excretion, particularly when other risk factors coexist.
Common pitfall: ACE inhibition is not direct blockade of the angiotensin receptor. Similar downstream effects do not make the molecular targets of these drug classes identical.
21.How does omeprazole inhibit gastric acid secretion?
Omeprazole suppresses gastric acid secretion through inhibition of the parietal-cell hydrogen–potassium ATPase, the final step in acid secretion. This differs from neutralizing acid already present in the stomach or blocking histamine receptors. Its pharmacological target explains why acid suppression is not simply proportional to the time the drug remains in plasma. Separate this mechanism from its formulation: enteric protection addresses acid instability before absorption, rather than being the acid-suppressing mechanism itself.
Apply it
A student compares an antacid with omeprazole. Explain that the antacid acts on existing gastric acid, whereas omeprazole inhibits the proton pump responsible for secretion. The distinction predicts different mechanisms even when both relieve acid-related symptoms.
Common pitfall: Enteric coating is a delivery feature, not receptor antagonism. Calling omeprazole an acid neutralizer confuses its molecular action with the effect of an antacid.
DailyMed — Omeprazole delayed-release capsules prescribing information
22.Why does warfarin affect synthesis rather than dissolve an existing clot?
Warfarin inhibits vitamin K recycling, reducing the formation of functional vitamin K-dependent clotting factors. Previously synthesized factors must decline before the full anticoagulant effect develops. The mechanism therefore differs from directly dissolving fibrin in an established clot or immediately neutralizing every circulating coagulation factor. Its effect is monitored with an appropriate coagulation measure, and both medicine interactions and changes in vitamin K intake can alter the response.
Apply it
A patient assumes that starting warfarin will immediately dissolve an existing clot. Explain that it reduces production of functional clotting factors and changes subsequent coagulation; it is not a fibrinolytic drug acting directly on the clot.
Common pitfall: Anticoagulation and thrombolysis are different processes. The presence of a clot does not make every antithrombotic medicine capable of directly breaking down fibrin.
23.How can receptor antagonism oppose a bronchodilator?
An antagonist can reduce an agonist's effect by preventing receptor activation. Beta blockers can oppose beta-agonist bronchodilation, and blockade involving airway beta-2 receptors can be especially relevant to bronchospasm. This is a pharmacodynamic interaction because the drugs oppose one another at the response pathway, rather than necessarily changing each other's concentration. Identify receptor selectivity and the patient's airway condition instead of treating every drug interaction as altered hepatic metabolism.
Apply it
A patient using a beta-2 agonist starts a medicine that blocks beta receptors and reports reduced bronchodilator benefit. The interaction hypothesis is opposing receptor effects; medication review should identify the specific blocker and the temporal relationship.
Common pitfall: A reduced drug effect does not always mean faster elimination. Receptor-level opposition can occur even when the agonist's measured concentration is unchanged.
24.How does an adverse event differ from an adverse drug reaction?
An adverse event is an undesirable occurrence during treatment without requiring an established causal relationship to the medicine. Calling it an adverse drug reaction adds a causal interpretation. Timing, known pharmacology, competing explanations and changes after withdrawal can inform assessment, but temporal sequence alone is insufficient proof. In Japan, healthcare professionals must report suspected harm when they judge reporting necessary to prevent health hazards or their expansion under Article 68-10(2), even when causality remains uncertain.
Apply it
A patient develops a rash after beginning a medicine, but also has a concurrent infection. Record the timing and competing explanation as part of a suspected reaction assessment. If the statutory health-protection criterion is met, report through PMDA without waiting for definitive attribution.
Common pitfall: An event occurring after treatment is not automatically caused by it. Equally, uncertain causality does not cancel a reporting duty once its statutory criterion is met.
薬剤師国家試験出題基準 — 平成28年11月22日 · PMDA — 医薬品医療機器等法に関する報告の制度について · 副作用が疑われる症例報告に関する情報 | 独立行政法人 医薬品医療機器総合機構
薬剤40/345 items; 11.59% calculated
25.Why can oral absorption exceed systemic bioavailability?
Absorption describes entry from the administration site, whereas systemic bioavailability is the fraction of an administered dose reaching systemic circulation unchanged. Presystemic metabolism in the intestinal wall or liver can reduce bioavailability after absorption. Thus, a medicine can be substantially absorbed while less unchanged parent drug becomes systemically available. Distinguish gastrointestinal degradation, incomplete absorption and first-pass loss when explaining low exposure; they are different processes with potentially different formulation or interaction implications.
Apply it
In a hypothetical study, most of an oral compound leaves the intestinal lumen, but only half the administered dose reaches systemic blood unchanged. Presystemic metabolism is one possible explanation; disappearance from the lumen alone does not establish complete systemic bioavailability.
Common pitfall: An enteric coating does not eliminate hepatic first-pass metabolism. Protection from stomach acid and avoidance of presystemic metabolism solve different pharmacokinetic problems.
薬剤師国家試験出題基準 — 平成28年11月22日 · DailyMed — Omeprazole delayed-release capsules prescribing information
26.What does an apparent distribution volume represent?
Define apparent distribution volume by X = Vd × C, where X is the amount of drug in the body and C is the corresponding plasma concentration. Rearranging gives Vd = X/C, with units of volume. This parameter expresses an amount-to-concentration relationship rather than identifying an anatomical container. For example, warfarin has a reported distribution volume of about 0.14 L/kg and approximately 99% plasma-protein binding. Interpretation must specify the concentration measured and the distribution model.
Apply it
Under an explicitly equilibrated model, 400 mg of a hypothetical drug remains in the body and its plasma concentration is 8 mg/L. Apparent distribution volume is 400/8 = 50 L. This calculation describes the stated amount-to-concentration relationship rather than a literal fluid compartment.
Common pitfall: A volume larger than plasma volume is not inherently impossible. Using the administered dose as the amount remaining after elimination has occurred would overestimate Vd.
薬剤師国家試験出題基準 — 平成28年11月22日 · DailyMed — Warfarin Sodium prescribing information
27.How do clearance and distribution volume determine half-life?
In a linear one-compartment model after input stops, assume constant Vd and elimination rate CL × C. Since X = Vd × C, dX/dt = −(CL/Vd)X, giving X/X0 = e^(−CLt/Vd). Setting X/X0 to one half yields t½ = ln(2) × Vd/CL, approximately 0.693 × Vd/CL. Thus, lower clearance lengthens half-life when Vd is unchanged. The warfarin label illustrates this relationship: its enantiomers have similar distribution volumes, while the more slowly cleared enantiomer has the longer half-life.
Apply it
A hypothetical drug has Vd 40 L and clearance 4 L/hour. Its calculated half-life is 6.93 hours. If clearance falls to 2 L/hour while Vd remains unchanged, the model predicts a half-life of 13.86 hours.
Common pitfall: The derivation assumes first-order elimination and constant distribution volume. Nonlinear elimination, ongoing absorption and multicompartment behaviour can invalidate a simple interpretation.
薬剤師国家試験出題基準 — 平成28年11月22日 · DailyMed — Warfarin Sodium prescribing information
28.Why does delayed-release omeprazole need intact enteric protection?
Omeprazole is acid-labile, so delayed-release formulations protect the drug during passage through the acidic stomach and permit release later. Enteric protection concerns the release location, whereas extended release concerns the time course of release. These terms are not interchangeable. With enteric-coated granules, preserving the granule coating is central to the formulation's function. Any manipulation must follow the instructions for the specific product rather than assumptions based only on the word capsule.
Apply it
A formulation exercise proposes grinding enteric-coated omeprazole granules to improve swallowing. Identify the loss of acid protection as the central problem and distinguish opening an authorized capsule preparation from crushing the protected granules themselves.
Common pitfall: A capsule shell is not always the release-controlling structure. Opening a capsule and destroying individual granule coatings can have very different pharmaceutical consequences.
DailyMed — Omeprazole delayed-release capsules prescribing information
29.How does dissolution rate differ from equilibrium solubility?
Solubility describes the amount that can dissolve at equilibrium under specified conditions. Dissolution rate describes how quickly a solid enters solution. Increasing exposed surface area can speed dissolution without necessarily changing equilibrium solubility. Crystal form, medium, temperature and pH can affect these properties in different ways. A formulation may therefore reach the same final dissolved concentration faster, rather than achieve a higher equilibrium concentration, and the distinction matters when interpreting release experiments.
Apply it
Two samples contain the same crystal form and mass but different particle sizes. Under otherwise identical conditions, the finer sample reaches the same final dissolved concentration sooner. This supports faster dissolution rather than a demonstrated increase in equilibrium solubility.
Common pitfall: A faster early concentration rise does not prove greater solubility. Comparisons must distinguish the approach to equilibrium from the final equilibrium state.
30.Why must a suspension be distinguished from a solution?
A solution contains molecularly dispersed solute, whereas a suspension contains dispersed solid particles that can settle. Uniform dose withdrawal from a suspension depends on restoring and maintaining adequate particle distribution according to the product's instructions. Sedimentation does not by itself establish chemical degradation, but a hard sediment that cannot redisperse can compromise dose uniformity. Distinguish a reversible physical separation from loss of potency, and distinguish both from a formulation that is genuinely dissolved.
Apply it
A training bottle labelled as a suspension has visible settling after storage. Before a simulated dose measurement, the learner follows its mixing instructions and checks that the sediment redistributes uniformly rather than drawing liquid only from the clear upper layer.
Common pitfall: Clear liquid above sediment is not necessarily the intended dose concentration. Conversely, visible settling alone does not prove that the active ingredient has chemically decomposed.
31.Why does urinary metabolite recovery differ from unchanged-drug renal elimination?
Urinary recovery can represent metabolites rather than unchanged parent drug. Omeprazole is extensively metabolized, and much of its dose appears in urine as metabolites; little unchanged omeprazole is recovered. A large urinary recovery therefore does not establish that the kidney directly clears most parent drug.
Apply it
Compare omeprazole with lisinopril, which is excreted unchanged in urine. Similar statements about urinary recovery can conceal different elimination pathways and different consequences of organ impairment.
Common pitfall: Identify the measured chemical species before inferring the route controlling parent-drug exposure.
薬剤師国家試験出題基準 — 平成28年11月22日 · DailyMed — Omeprazole delayed-release capsules prescribing information · DailyMed — Lisinopril tablets prescribing information
病態・薬物治療40/345 items; 11.59% calculated
32.How should an adult's insulin-associated hypoglycemia be recognized and treated immediately?
Blood glucose below 70 mg/dL is a commonly used recognition threshold, alongside the person's individualized target. Sweating, shaking, hunger and confusion are relevant cues, but impaired awareness can remove warning symptoms. An alert adult who can swallow generally takes 15–20 g of rapid glucose or carbohydrate immediately, checks glucose after 15 minutes and repeats treatment if still low, respecting individualized instructions. If swallowing is unsafe, give nothing orally and obtain emergency assistance; use prescribed glucagon when available and a helper knows how.
Apply it
An adult using insulin misses lunch, becomes sweaty and shaky, and measures glucose at 58 mg/dL. Because the adult is alert and swallowing safely, give 15–20 g of rapid glucose or carbohydrate and recheck after 15 minutes. Repeat if glucose remains low. After recovery, a snack is appropriate if the next meal is more than an hour away.
Common pitfall: Confusion can progress to unsafe swallowing. Never put food or drink into an unconscious person's mouth. When carbohydrate digestion is slowed by a diabetes medicine, glucose tablets or gel provide the appropriate rapid glucose source.
33.When should asthma treatment include an inhaled anti-inflammatory controller instead of escalating a reliever alone?
Persistent symptoms, recurrent nocturnal waking, increasing albuterol use or diminishing relief indicate inadequate asthma control. In a stable adult using a bronchodilator reliever alone, persistent symptoms despite correct inhaler technique support initiating inhaled corticosteroid-containing treatment. Inhaled corticosteroids treat airway inflammation, a foundation of long-term asthma management identified in Japanese product information. Albuterol relaxes airway smooth muscle and relieves bronchoconstriction, but increasing it alone does not supply the missing anti-inflammatory treatment. Confirm technique and actual medicine use when assessing control, and distinguish long-term treatment selection from management of an acute severe attack.
Apply it
An adult with established asthma uses only an albuterol reliever and continues to awaken with wheeze several nights each week. Demonstration confirms correct inhaler technique. These persistent nocturnal symptoms support adding inhaled corticosteroid-containing controller treatment through the prescriber. Simply increasing the bronchodilator alone would provide temporary airway opening without adequately treating the underlying inflammation. Subsequent assessment should examine nocturnal waking, daytime symptoms and reliever use.
Common pitfall: Short-lived relief after albuterol does not establish adequate long-term control. Specify the inhaled route when recommending corticosteroid-containing controller treatment; this recommendation does not mean routinely starting oral corticosteroids. Correct technique cannot compensate for an absent anti-inflammatory controller. Acute severe breathlessness requires urgent assessment.
薬剤師国家試験出題基準 — 平成28年11月22日 · DailyMed — Albuterol Sulfate HFA prescribing information · 14987901086209
34.When should indexed eGFR be converted to mL/min?
Laboratories often report eGFR normalized to a body surface area of 1.73 m². When a drug decision requires an absolute filtration estimate in mL/min, de-indexing uses eGFR × actual body surface area/1.73. This matters especially when body size differs substantially from the indexing standard. Conversion does not make eGFR interchangeable with every creatinine-clearance estimate; the medicine's dosing evidence and specified renal measure still determine which estimate is appropriate.
Apply it
A hypothetical dosing reference explicitly requires absolute eGFR. A patient has indexed eGFR 50 mL/min/1.73 m² and body surface area 1.38 m². De-indexing gives approximately 40 mL/min, before applying that reference's decision criteria.
Common pitfall: An indexed result is not automatically an absolute clearance. Removing the body-surface-area units without conversion can misclassify patients whose body size differs from the standard.
NIDDK — Determining Drug Dosing in Adults with Chronic Kidney Disease
35.Why can serum creatinine mislead renal dosing decisions?
Creatinine reflects both renal removal and creatinine generation, which is influenced by muscle mass and other factors. A low concentration in a person with little muscle does not necessarily indicate strong filtration. Creatinine-based estimates are also less reliable when kidney function is changing rapidly because steady-state assumptions may fail. Consider the clinical trend and situations where additional assessment, including cystatin C-based information, could improve a decision near a consequential dosing boundary.
Apply it
A frail patient with very low muscle mass has a seemingly reassuring creatinine value, but a renally cleared medicine requires careful assessment. Treat the isolated value cautiously and evaluate the suitability of the renal estimate before choosing a regimen.
Common pitfall: A laboratory value inside its reference interval does not guarantee normal drug clearance. Formula precision cannot compensate for a biological marker that poorly represents the patient.
NIDDK — Determining Drug Dosing in Adults with Chronic Kidney Disease
36.Which patient factors increase ACE inhibitor-associated hyperkalemia risk?
ACE inhibition can reduce aldosterone-mediated potassium excretion. Renal impairment, diabetes and concurrent potassium supplements, potassium-containing salt substitutes or potassium-sparing medicines increase concern for hyperkalemia. A rising potassium result should be interpreted with the medication list, kidney function and clinical context rather than attributed to diet alone. The decision is to identify interacting contributors and arrange an appropriate clinical response; a normal prior value does not exclude a new risk after treatment changes.
Apply it
A patient with kidney impairment starts lisinopril and independently replaces table salt with a potassium-containing substitute. A later potassium result rises. Link reduced potassium excretion and the new potassium source when preparing the medication review.
Common pitfall: Products marketed as salt substitutes are not automatically suitable for every patient. A sodium-reduction goal does not remove the risk created by substantial potassium intake.
37.How does documented erosive reflux disease guide acid-suppressing treatment selection?
For endoscopically documented acid-mediated erosive esophagitis, the objectives include mucosal healing and symptom relief. A proton-pump inhibitor is favoured over H2-receptor-antagonist monotherapy by the cited comparative healing evidence. Concomitant clopidogrel changes agent selection: avoid omeprazole with clopidogrel because it reduces formation of clopidogrel's active metabolite.
Apply it
An adult has reflux symptoms and confirmed esophageal erosions. Select a PPI-based healing strategy; if clopidogrel is present, exclude omeprazole from the proposed combination.
Common pitfall: Symptom relief alone does not establish healing. An interaction involving one PPI does not establish identical interaction magnitude for every PPI.
薬剤師国家試験出題基準 — 平成28年11月22日 · DailyMed — Omeprazole delayed-release capsules prescribing information
38.How do absolute risk reduction and number needed to treat express benefit?
Absolute risk reduction is control-event risk minus treatment-event risk over a defined period. Number needed to treat is its reciprocal when risks are expressed as proportions, conventionally rounded upward to a whole person. These measures communicate benefit alongside baseline risk and follow-up duration. Relative risk reduction alone can sound impressive when the absolute change is small. Check that the same outcome and observation period are used and consider uncertainty before translating a study result into practice.
Apply it
In a hypothetical trial over one year, an outcome occurs in 8% of controls and 6% of treated participants. Absolute reduction is 0.02, relative reduction is 25%, and number needed to treat is 50 for that outcome and period.
Common pitfall: Using percentage points as whole numbers gives an incorrect reciprocal. Number needed to treat also changes with baseline risk, outcome definition and follow-up duration.
薬剤師国家試験出題基準 — 平成28年11月22日 · CDC Field Epidemiology Manual — Analyzing and Interpreting Data
法規・制度・倫理30/345 items; 8.70% calculated
39.What legally distinguishes passing the examination from pharmacist licensure?
Under Japan's Pharmacists Act, pharmacist status requires a licence from the Minister of Health, Labour and Welfare, with licensing linked to registration in the pharmacist register. Passing the national examination is a qualification requirement, not a substitute for the licensing process. Separate examination results, eligibility documentation and professional registration when evaluating a scenario. A person who has passed should not assume that the result notice alone authorizes practice as a licensed pharmacist.
Apply it
A graduate receives a passing result and is offered work explicitly requiring pharmacist licensure before registration has been completed. Identify the missing licensing step rather than treating the examination result itself as evidence of an issued licence.
Common pitfall: Academic graduation, examination success and professional registration are related but distinct events. Completing one does not automatically establish completion of every legal requirement.
40.When does changing a prescription require prescriber consent?
The Pharmacists Act restricts a pharmacist from changing prescribed medicines without the consent of the prescriber who issued the prescription. A suspected error should therefore trigger clarification and an authorized resolution rather than an independent substitution of the pharmacist's preferred regimen. Distinguish a clinical concern from legal authority to change the order. A patient's agreement or a pharmacist's confidence in the likely intention does not replace the prescriber's required consent.
Apply it
A prescription appears to contain the wrong strength, and the patient says a lower strength was probably intended. Contact the issuing prescriber to obtain an authorized correction instead of changing the strength solely on the patient's recollection.
Common pitfall: A plausible correction is still a change. Knowing the usual regimen does not establish the prescriber's actual intention or supply the required authorization.
41.How should unresolved prescription doubt affect dispensing?
When a pharmacist finds a doubtful point in a prescription, the Pharmacists Act requires inquiry to the issuing prescriber and resolution before dispensing on that prescription. The duty concerns an unresolved doubt, not only an already proven error. Identify the exact ambiguity, gather relevant patient information and communicate it clearly. The legal distinction is between confirming what may safely be dispensed and guessing an intended order because the patient is waiting.
Apply it
A prescription's administration frequency conflicts with a documented recent instruction, and neither source clearly supersedes the other. Describe the discrepancy to the issuing prescriber and resolve it before dispensing according to an assumed frequency.
Common pitfall: Patient urgency does not itself resolve a doubtful instruction. Dispensing first and asking later reverses the required sequence when the prescription remains uncertain.
42.How does respect for autonomy guide medicine counselling?
Respect for autonomy means helping a person make an informed decision consistent with their values, while beneficence and nonmaleficence require attention to benefit and harm. Explain relevant choices in understandable terms, explore concerns and check understanding rather than equating agreement with comprehension. Ethical counselling can include a patient's informed refusal. The pharmacist should clarify consequences and communicate relevant concerns without using pressure or withholding information to secure the preferred choice.
Apply it
A patient hesitates to start a medicine because of feared adverse effects. Explore the concern, explain likely benefits and material risks, and check understanding before discussing the patient's preference and communicating unresolved issues to the treatment team.
Common pitfall: Simply telling a patient that treatment is necessary does not establish informed agreement. Respectful support also differs from accepting a decision made through misunderstanding.
43.When is reporting a suspected reaction legally required in Japan?
Under Article 68-10(2) of the Pharmaceuticals and Medical Devices Act, healthcare professionals must report relevant suspected medicine-related harm when they judge reporting necessary to prevent health hazards or their expansion. This is a conditional legal obligation: once that health-protection criterion is met, reporting is required. Reports to the Minister of Health, Labour and Welfare are received through PMDA. Definitive causality is unnecessary, and a reaction need not be unexpected to warrant reporting.
Apply it
A pharmacist identifies a serious suspected reaction and judges reporting necessary to protect health, although another cause remains possible. Submit the report through PMDA and describe the uncertainty; do not wait for every competing explanation to be excluded.
Common pitfall: Professional judgment determines whether the statutory criterion is met; it does not make reporting optional after that determination. Uncertain causality does not remove the duty.
PMDA — 医薬品医療機器等法に関する報告の制度について · 副作用が疑われる症例報告に関する情報 | 独立行政法人 医薬品医療機器総合機構
実務95/345 items; 27.54% calculated
44.How is a best possible medication history assembled?
A useful medication history combines a patient or caregiver interview with other reliable information, such as medicine containers, dispensing records and existing lists. Record what is actually taken, including nonprescription medicines and supplements, rather than copying a prescription list uncritically. Name, strength, amount, route, frequency and recent use help distinguish active therapy from historical entries. Disagreement between sources should be investigated because each can be incomplete or out of date.
Apply it
At admission, an electronic list shows three medicines, while the patient brings five containers and reports a supplement. Compare the sources and establish current use before treating the electronic list as the complete medication history.
Common pitfall: A dispensing record demonstrates supply rather than actual ingestion. A patient interview is essential, but memory alone may omit names, strengths or recently discontinued medicines.
AHRQ — MATCH Toolkit for Medication Reconciliation: Introduction
45.How does reconciliation resolve a medication discrepancy?
Medication reconciliation compares an established medication history with current orders at a transition of care, identifies differences and determines whether each difference is intended. It is more than creating a tidy list. An omission may be deliberate, accidental or temporarily necessary, so the pharmacist must establish intent and communicate the resolved plan. Documenting the reason for a change helps the next clinician and patient avoid unintentionally restarting, duplicating or stopping therapy.
Apply it
A long-term medicine is absent from a discharge list. Instead of automatically adding it back, establish whether it was intentionally stopped during admission and ensure that the final list and explanation match the authorized discharge plan.
Common pitfall: Every difference is not necessarily an error. Automatically restoring the previous regimen can undo an intentional clinical change and create a new medication problem.
AHRQ — MATCH Toolkit for Medication Reconciliation: Introduction
46.Why should duplicate therapy be checked by active ingredient?
Different product names can conceal the same active ingredient, and combination products can duplicate one component of another medicine. Compare ingredients, strengths, routes and actual use rather than relying on brand names or package appearance. The practical task is to determine whether concurrent use is intended and safe, not to assume every shared ingredient is an error. Reconciliation provides the context needed to distinguish a historical entry from a true duplicate exposure.
Apply it
A patient lists a prescription product and a nonprescription combination medicine under unrelated brand names. Comparing ingredients reveals the same active ingredient in both. Clarify actual use and total exposure before recommending how to resolve the overlap.
Common pitfall: Counting products does not measure the number of active drugs. Conversely, a shared ingredient on two lists does not prove simultaneous use until current use is confirmed.
AHRQ — MATCH Toolkit for Medication Reconciliation: Introduction · 薬剤師国家試験出題基準 — 平成28年11月22日
47.Which details make a medicine allergy history clinically useful?
A useful reaction history records the suspected medicine, the reaction's features, timing, severity, treatment and any subsequent exposure. This helps distinguish a potentially immune-mediated reaction from a predictable adverse effect or an uncertain historical label. The pharmacist should preserve uncertainty rather than independently deleting a warning after a brief conversation. Detailed documentation supports appropriate assessment and prevents both unsafe re-exposure and unnecessary restriction caused by an unexplained entry such as allergy unknown.
Apply it
A record says only that a medicine caused an allergy. The patient recalls nausea without rash, breathing difficulty or swelling. Document the reported features and timing for clinical review rather than automatically confirming allergy or erasing the existing alert.
Common pitfall: A vague allergy label is not a complete diagnosis. Reclassifying it without adequate assessment can be as misleading as retaining an inaccurate label without clarification.
48.How does teach-back reveal a counselling gap?
Teach-back asks the patient to explain key instructions in their own words so the clinician can assess how clearly the information was communicated. It is a check on the explanation, not a test of the patient's intelligence. Use a nonjudgmental invitation, identify gaps, explain again in a different way and repeat the check. Agreement, nodding or a yes to understanding cannot show whether the patient can actually apply the instructions at home.
Apply it
After explaining a new schedule, say that you want to check your explanation and ask the patient to describe when each medicine will be taken tomorrow. Correct any mismatch, then invite another explanation using the revised plan.
Common pitfall: Asking whether the patient understands invites a socially easy yes. Asking them to repeat your exact words may test memory without demonstrating practical understanding.
AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition — Tool 5
49.Why should inhaler counselling include an observed demonstration?
Device instructions require coordinated actions, so verbal recall alone may not reveal technique errors. Ask the patient to demonstrate use with the relevant device or training device, compare the actions with its instructions and correct specific steps. Re-demonstration confirms whether the explanation changed performance. Device type matters because inhalation manoeuvres and preparation steps are not universal. This approach separates delivery failure from a conclusion that the medicine itself has no pharmacological effect.
Apply it
A patient can name the inhaler's purpose but reports little benefit. An observed demonstration reveals that an essential device step is omitted. Demonstrate the correct technique, then have the patient show it again before judging the treatment ineffective.
Common pitfall: One generic inhaler demonstration does not fit every device. Recognizing the product name or describing the steps is weaker evidence than correctly performing them.
AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition — Tool 5 · DailyMed — Albuterol Sulfate HFA prescribing information
50.How should vitamin K intake and specific Japanese food precautions be discussed with a warfarin user?
For ordinary foods, maintain a reasonably consistent dietary vitamin K pattern and discuss substantial changes; eliminating every green vegetable is unnecessary. Explicitly distinguish natto, chlorella products and aojiru, which Japanese PMDA guidance advises avoiding during warfarin treatment. Their vitamin K exposure can reduce anticoagulant effect. Natto also contains bacteria capable of producing vitamin K, and its influence can persist for days, so separating it from the warfarin dose does not reliably prevent the interaction.
Apply it
A patient proposes a daily leafy-green smoothie and natto several hours after warfarin. Discuss the major dietary change and monitoring, advise avoiding natto, chlorella products and aojiru, and explain why dose separation does not make natto acceptable.
Common pitfall: Dietary consistency does not override these specific avoidance precautions. Avoid sustained excessive intake of vitamin K-rich leafy vegetables, and include supplements in the history.
DailyMed — Warfarin Sodium prescribing information · Q3 ワルファリンを飲んでいますが、納豆、クロレラ、青汁などの摂取を避けるように指導されました。なぜ、食べてはいけないのですか？ | 独立行政法人 医薬品医療機器総合機構
51.When should bleeding counselling become urgent escalation?
Counselling should distinguish routine prevention from symptoms requiring urgent assessment. During warfarin therapy, uncontrolled bleeding or signs suggesting internal bleeding should not be managed solely by reassuring the patient or adjusting diet. Ask focused questions about the symptom, onset, severity, associated weakness or neurological changes, and recent medicines while arranging appropriate urgent evaluation. Information gathering supports escalation but should not delay it when the reported features suggest serious harm.
Apply it
During a refill conversation, a warfarin user reports vomiting blood. Move from routine adherence counselling to urgent medical assessment and communicate the anticoagulant history. Do not spend the encounter first trying to calculate dietary vitamin K intake.
Common pitfall: A refill encounter can reveal an emergency. The routine nature of the original visit should not determine the response to newly disclosed serious symptoms.
52.How should swallowing difficulty be handled with enteric-coated granules?
First identify the exact product and the structure responsible for release control. Enteric-coated omeprazole granules require protection from crushing or chewing because damage can expose acid-labile drug before absorption. Some labelled preparations permit specified ways of opening a capsule, but those instructions cannot be transferred automatically between products. A useful counselling decision preserves the protected particles and uses an authorized administration method suited to the patient's swallowing ability.
Apply it
A patient asks whether a delayed-release omeprazole capsule can be ground into powder. Explain the role of intact coated granules, then check the particular product's authorized administration options to find a suitable approach for the swallowing problem.
Common pitfall: Permission to open one capsule does not authorize pulverizing its contents. Product-specific alternatives must preserve the relevant release feature rather than merely make the medicine easier to swallow.
DailyMed — Omeprazole delayed-release capsules prescribing information · AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition — Tool 5
53.How can an adherence barrier be identified without blame?
Ask how the patient actually uses the medicine and what makes the plan difficult. Missed treatment can reflect misunderstanding, adverse effects, cost, access, dexterity, swallowing problems or an incompatible daily routine. Each mechanism calls for a different response, so repeating the same instruction without identifying the barrier may fail. Use an open, neutral question and confirm the resulting plan through teach-back rather than interpreting an incomplete refill history as proof of unwillingness.
Apply it
A patient repeatedly misses a midday medicine because it is stored at home during work. Explore the routine and discuss feasible, authorized solutions with the team, instead of assuming that another warning about adherence will resolve the problem.
Common pitfall: A reminder system cannot solve every barrier. If the patient is avoiding a medicine because of adverse effects, more reminders leave the underlying concern unaddressed.
AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition — Tool 5 · AHRQ — MATCH Toolkit for Medication Reconciliation: Introduction
54.Which renal information should accompany a dosing clarification?
A renal dosing discussion should identify the medicine, current regimen, renal estimate and units, relevant body size, measurement date and trend. Specify whether the result is indexed eGFR, absolute eGFR or another clearance estimate, because identical numbers can represent different quantities. Explain the particular dosing boundary or accumulation concern rather than sending an isolated laboratory value. Also flag rapidly changing function or unusual muscle mass when these limit the estimate's reliability.
Apply it
A dosing reference uses mL/min, while the chart reports eGFR per 1.73 m². Include body surface area, the appropriate converted result and the reference's renal measure when asking the prescriber to review the regimen.
Common pitfall: A message saying only that renal function is low does not explain the decision. A precise number without its units or clinical limitations can be equally misleading.
NIDDK — Determining Drug Dosing in Adults with Chronic Kidney Disease
55.Why must therapeutic drug monitoring include sample timing?
A measured drug concentration is interpretable only in relation to dose history, sampling time, route, formulation and the monitoring method. Concentrations vary across a dosing interval and may change before steady state or after altered clearance. Record actual administration and collection times rather than assuming a sample is a trough because it was ordered as one. A mistimed sample can produce an inappropriate dose change even when the laboratory measurement itself is analytically accurate.
Apply it
A concentration requested before the next dose is collected shortly after administration instead. Record the actual times and seek interpretation appropriate to that sample rather than comparing it uncritically with a pre-dose target.
Common pitfall: An accurate assay does not guarantee a clinically interpretable result. Labelling a mistimed sample as a trough does not change the concentration profile it represents.
56.How does mass conservation guide a dilution calculation?
For a simple dilution without loss or reaction, solute amount remains constant, giving C1V1 = C2V2 when concentrations use compatible units. The final volume includes the stock solution; it is not necessarily the volume of diluent added. Establish whether concentrations are mass per volume, percentage or another expression before calculating. The equation determines quantities only and does not demonstrate compatibility, sterility, stability or suitability for administration.
Apply it
In a hypothetical nonclinical exercise, prepare 100 mL of 2 mg/mL solution from 10 mg/mL stock. Required solute is 200 mg, so use 20 mL stock and bring the total volume to 100 mL.
Common pitfall: Adding 100 mL of diluent to 20 mL of stock does not produce a final volume of 100 mL. Correct arithmetic also does not validate a preparation procedure.
57.How is a prescribed quantity separated from a dosing recommendation?
A dispensing quantity follows from the authorized amount per administration, administrations per day and treatment duration, adjusted for the dosage unit. Keep mass, volume and unit counts separate so dimensional analysis exposes errors. Calculating the supply does not establish that the prescribed regimen is clinically appropriate; prescription review is a separate step. State assumptions explicitly when an exercise provides a hypothetical regimen, and do not silently replace the prescribed directions with a customary schedule.
Apply it
A hypothetical authorized exercise specifies two tablets per administration, three administrations daily for seven days. The required quantity is 42 tablets. This verifies supply arithmetic while leaving clinical appropriateness to the separately specified prescription-review process.
Common pitfall: Multiplying the tablet strength again when counting tablets confuses dose mass with unit quantity. A mathematically correct supply can still accompany an inappropriate or unresolved prescription.
58.Which clinical details strengthen a suspected-reaction report?
A useful suspected-reaction report describes the patient, suspected medicine, exposure dates, event onset, clinical findings, seriousness, management and outcome. Concomitant medicines and competing explanations help assessment rather than weakening the report. Record what happened after stopping or changing treatment when known, without deliberately re-exposing a patient to prove causality. Separate observed facts from interpretations. When the Article 68-10(2) health-protection criterion is met, submit through PMDA despite remaining causal uncertainty.
Apply it
A suspected reaction occurs after a new medicine. Assemble the start date, symptom onset, laboratory changes, other medicines and outcome after clinical management, then describe the possible alternative cause rather than omitting it to make the report seem stronger.
Common pitfall: A long report without a clear timeline may be less informative than a concise chronological account. Reporting does not require a hazardous deliberate rechallenge.
PMDA — 医薬品医療機器等法に関する報告の制度について · 副作用が疑われる症例報告に関する情報 | 独立行政法人 医薬品医療機器総合機構
59.How does SOAP documentation separate evidence from interpretation?
SOAP organizes subjective information, objective findings, assessment and plan. A patient's report belongs in subjective information; measured results belong in objective information; the pharmacist's interpretation belongs in assessment; and intended actions belong in the plan. This separation helps another clinician understand both the evidence and the reasoning. Document uncertainty and follow-up responsibility clearly, because a plan that lacks ownership or a review point may not produce the intended monitoring or clarification.
Apply it
A patient reports dizziness, blood pressure is measured, and a medicine contribution is suspected. Record the symptom, measurement, interpretation and agreed communication or monitoring action in their respective SOAP sections so the next clinician can follow the reasoning.
Common pitfall: Writing a suspected cause as an objective fact overstates certainty. Recording only a problem without an actionable plan leaves the next person unsure what should happen.
60.What makes a discharge medication handoff actionable?
An actionable handoff communicates the reconciled current regimen, what started, stopped or changed, the reasons for those changes and any unresolved monitoring needs. The patient needs understandable instructions, while receiving professionals need enough detail to continue the plan safely. Confirm access to the medicines and use teach-back for important changes. A copied list without explanations can allow discontinued therapy to restart or leave a patient taking both old and new instructions.
Apply it
A discharge regimen replaces an earlier schedule and requires follow-up monitoring. Provide the final list, identify the superseded instructions, explain the change to the patient and communicate who will arrange and review the monitoring.
Common pitfall: Giving several inconsistent lists transfers reconciliation work to the patient. A complete list also remains insufficient if the patient cannot obtain or correctly use the medicines.
AHRQ — MATCH Toolkit for Medication Reconciliation: Introduction · AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition — Tool 5
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give 実務 the largest share of practice, linking each patient decision to its scientific, therapeutic or legal basis.
- Protect essential-question knowledge in every subject; a strong aggregate does not replace subject-level essential performance.
- Write units and assumptions before buffer, absorbance, pharmacokinetic, renal-function and dispensing calculations.
- Distinguish molecular target, physiological effect, adverse effect and the clinical action each finding supports.
- Compare therapeutic regimens using disease findings, treatment objectives and patient factors, including asthma controller needs and erosive reflux healing.
- Practise Japanese prescription clarification, authorized changes, registration and mandatory PMDA reporting when the statutory criterion is met.
- Use the complete official outline to extend this selective guide into omitted disease groups, natural products, environmental health, healthcare systems and formulation topics.
A practical preparation plan
1. Map the full seven-subject scope
Read the applicable official outline and mark each topic as secure, developing or unstudied. Use the official subject item totals to distribute study time while retaining regular work in every essential subject.
2. Build mechanism-to-decision chains
For each medicine, state its target, downstream effect, relevant adverse effect and patient finding that changes the decision. For treatment-selection cases, identify the disease findings, objective, preferred class, patient factor and reason a plausible alternative is less suitable.
3. Calculate with explicit quantities
Work calculations without looking at the answer. Label concentrations, volumes, times and renal-function units, then check whether the result is physically and clinically interpretable under the stated assumptions.
4. Link practical cases across subjects
For a prescription or transition-of-care case, establish actual medicine use, identify the problem, apply the relevant mechanism or law and write a clear communication plan. Practise both clarification and patient explanation.
5. Review every alternative after the test
Complete the 20 independent questions, then explain why each competing option is less appropriate. Record whether an error arose from missing knowledge, an overlooked cue, unit handling or an unsupported assumption.
6. Space recall and expand coverage
Use the flashcards for repeated active recall and revisit uncertain mechanisms with their cases. Add official released questions in their original formats and work through remaining outline topics before undertaking practice matched to the published examination sessions.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- 薬剤師国家試験 — 第112回薬剤師国家試験の施行
- 薬剤師国家試験出題基準 — 平成28年11月22日
- 新薬剤師国家試験について — amended through 2018-08-31
- 新たな薬剤師国家試験出題基準を策定しました
- 薬剤師国家試験出題基準改定に係る経緯について
- 薬剤師国家試験出題基準改定部会 — 2026-06-01 meeting minutes
- Chemistry 2e — 14.6 Buffers
- Organic Chemistry — 5.1 Enantiomers and the Tetrahedral Carbon
- 「医薬部外品原料規格２００６」の一部改正について — 2011-12-19
- CDC Pink Book — Chapter 1: Principles of Vaccination
- CDC Field Epidemiology Manual — Analyzing and Interpreting Data
- CDC — Clinical Guidance for Carbon Monoxide Poisoning
- DailyMed — Lisinopril tablets prescribing information
- DailyMed — Albuterol Sulfate HFA prescribing information
- DailyMed — Omeprazole delayed-release capsules prescribing information
- NIDDK — Low Blood Glucose (Hypoglycemia)
- 薬剤師法
- PMDA — 医薬品医療機器等法に関する報告の制度について
- AHRQ — MATCH Toolkit for Medication Reconciliation: Introduction
- AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition — Tool 5
- NIDDK — Determining Drug Dosing in Adults with Chronic Kidney Disease
- DailyMed — Warfarin Sodium prescribing information
- 副作用が疑われる症例報告に関する情報 | 独立行政法人 医薬品医療機器総合機構
- Q3 ワルファリンを飲んでいますが、納豆、クロレラ、青汁などの摂取を避けるように指導されました。なぜ、食べてはいけないのですか？ | 独立行政法人 医薬品医療機器総合機構
- 14.6 Buffers - Chemistry: Atoms First | OpenStax
- 5.5 Sequence Rules for Specifying Configuration - Organic Chemistry | OpenStax
- 7.4 Oxidative Phosphorylation - Biology for AP® Courses | OpenStax
- Mechanism of Action Assays for Enzymes - Assay Guidance Manual - NCBI Bookshelf
- 001674775.pdf
- 14987901086209
- 300119_3399008F1203_1_12
- PMDA）医薬関係者からの報告「報告受付サイト」とは
- 530113_2259004Q1200_2_05
- Serendipitous discovery of a prodrug of a PARP-1 inhibitor - PubMed
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.